Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.
De Philippis C, Zucchinetti C, Mannina D, Krampera M, Zinzani PL, Chiappella A, di Rocco A, Orcioulo E, Tisi MC, Pistolese F, Giordano L, Santoro A, Bramanti S. De Philippis C, et al. Among authors: di rocco a. Bone Marrow Transplant. 2024 Apr;59(4):569-571. doi: 10.1038/s41409-024-02205-6. Epub 2024 Jan 25. Bone Marrow Transplant. 2024. PMID: 38272998 No abstract available.
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.
Zinzani PL, Rossi G, Franceschetti S, Botto B, Di Rocco A, Cabras MG, Petti MC, Stefoni V, Broccoli A, Fanti S, Pellegrini C, Montini GC, Gandolfi L, Derenzini E, Argnani L, Fina M, Tucci A, Bottelli C, Pileri S, Baccarani M. Zinzani PL, et al. Among authors: di rocco a. Clin Cancer Res. 2010 Aug 1;16(15):3998-4004. doi: 10.1158/1078-0432.CCR-10-0162. Epub 2010 Jun 11. Clin Cancer Res. 2010. PMID: 20542986 Free article. Clinical Trial.
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma.
Rossi D, Rasi S, Di Rocco A, Fabbri A, Forconi F, Gloghini A, Bruscaggin A, Franceschetti S, Fangazio M, De Paoli L, Bruna R, Capello D, Chiappella A, Lobetti Bodoni C, Giachelia M, Tisi MC, Pogliani EM, Lauria F, Ladetto M, Hohaus S, Martelli M, Vitolo U, Carbone A, Foà R, Gaidano G. Rossi D, et al. Among authors: di rocco a. Blood. 2011 Feb 24;117(8):2405-13. doi: 10.1182/blood-2010-07-296244. Epub 2010 Dec 14. Blood. 2011. PMID: 21156845 Free article.
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study.
Carella AM, de Souza CA, Luminari S, Marcheselli L, Chiappella A, di Rocco A, Cesaretti M, Rossi A, Rigacci L, Gaidano G, Merli F, Spina M, Stelitano C, Hohaus S, Barbui A, Puccini B, Miranda EC, Guida A, Federico M. Carella AM, et al. Among authors: di rocco a. Leuk Lymphoma. 2013 Jan;54(1):53-7. doi: 10.3109/10428194.2012.691482. Epub 2012 Sep 28. Leuk Lymphoma. 2013. PMID: 22712840
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.
Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaccaria A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Tura S, Vitolo U. Zinzani PL, et al. Among authors: di rocco a. Leuk Lymphoma. 2015 Jun;56(6):1671-6. doi: 10.3109/10428194.2014.964702. Epub 2014 Nov 19. Leuk Lymphoma. 2015. PMID: 25241999
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.
Zinzani PL, Rigacci L, Cox MC, Devizzi L, Fabbri A, Zaja F, Di Rocco A, Rossi G, Storti S, Fattori PP, Argnani L, Vitolo U. Zinzani PL, et al. Among authors: di rocco a. Leuk Lymphoma. 2017 Jan;58(1):226-229. doi: 10.1080/10428194.2016.1184755. Epub 2016 Jun 2. Leuk Lymphoma. 2017. PMID: 27252040 No abstract available.
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma.
Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, Mannina D, Tani M, Rusconi C, Romano A, Vanazzi A, Botto B, Carlo-Stella C, Hohaus S, Musto P, Mazza P, Molica S, Corradini P, Fama A, Gaudio F, Merli M, Gravetti A, Gritti G, Arcari A, Tosi P, Liberati AM, Pinto A, Pavone V, Gherlinzoni F, Naso V, Volpetti S, Trentin L, Goldaniga MC, Bonfichi M, De Renzo A, Schiavotto C, Spina M, Storti S, Carella AM, Stefoni V, Argnani L, Zinzani PL. Broccoli A, et al. Among authors: di rocco a. Haematologica. 2017 Nov;102(11):1931-1935. doi: 10.3324/haematol.2017.171355. Epub 2017 Aug 3. Haematologica. 2017. PMID: 28775121 Free PMC article.
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.
Ceriani L, Milan L, Martelli M, Ferreri AJM, Cascione L, Zinzani PL, Di Rocco A, Conconi A, Stathis A, Cavalli F, Bellei M, Cozens K, Porro E, Giovanella L, Johnson PW, Zucca E. Ceriani L, et al. Among authors: di rocco a. Blood. 2018 Jul 12;132(2):179-186. doi: 10.1182/blood-2018-01-826958. Epub 2018 May 2. Blood. 2018. PMID: 29720487 Free article.
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death.
Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR, Hohaus S, Sciarra R, Re A, Tecchio C, Chiappella A, Morello L, Gini G, Nassi L, Perrone T, Molinari AL, Fabbri A, Cox MC, Finolezzi E, Ferrero S, Puccini B, Alvarez De Celis I, Arcari A, Marino D, Merli M, Piazza F, Gentile M, Pelosini M, Loseto G, Hermine O, Dreyling M, Ruggeri M, Martelli M, Hoster E, Vitolo U; Fondazione Italiana Linfomi and the Mantle Cell Lymphoma Network. Visco C, et al. Among authors: di rocco a. Br J Haematol. 2019 Jun;185(5):940-944. doi: 10.1111/bjh.15643. Epub 2018 Nov 8. Br J Haematol. 2019. PMID: 30407625 Free article. No abstract available.
226 results